Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
CJSB462B12201
Prostate Cancer Phase II
- 8.4 weeks
CLOU064P12301 (REMASTER)
Secondary progressive multiple sclerosis Phase III
- 7.6 weeks
- Co-1st site activated in Canada
CLOU064P12301 (REMASTER)
Secondary progressive multiple sclerosis Phase III
- 8 weeks
CLOU064P12301 (REMASTER)
Secondary progressive multiple sclerosis Phase III
- 12.4 weeks
CLOU064P12301 (REMASTER)
Secondary progressive multiple sclerosis Phase III
- 15.4 weeks
CMAS825J12201
Still's Disease Phase II
- 8.4 weeks
- 2nd site activated worldwide
CMAS825J12201
Still's Disease Phase II
- 10.2 weeks
- 3rd site activated worldwide
CO45042 (KRAScendo-2)
Oncology (Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer) Phase III
- 9.2 weeks
CO45042 (KRAScendo-2)
Oncology (Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer) Phase III
- 9.6 weeks
CO45042 (KRAScendo-2)
Advanced or metastatic non-squamous non Small cell lung cancer Phase III
- 9.2 weeks
- 1st site activated in Canada
CO45042 (KRAScendo-2)
Advanced or metastatic non-squamous non Small cell lung cancer Phase III
- 9.6 weeks
CO45042 (KRAScendo-2)
Advanced or metastatic non-squamous non Small cell lung cancer Phase III
- 8 weeks
CO45813
Oncology Phase II
- 10 weeks
CO45813
Oncology Phase II
- 13.4 weeks
D6972C00002
Chronic Kidney Disease and High Blood Pressure Phase III
- 7.8 weeks
D6972C00002
Chronic Kidney Disease and High Blood Pressure Phase III
- 11.4 weeks
D6972C00002
Chronic Kidney Disease and High Blood Pressure Phase III
- 14.6 weeks
DFI17808
Myotonic Dystrophy Phase I/II
- 16.8 weeks
- 1st site activated in Canada
EFC18244 (THESEUS)
Chronic Obstructive Pulmonary Disease (COPD) Phase IIb/III
- 8.6 weeks
EFC18244 (THESEUS)
Chronic Obstructive Pulmonary Disease (COPD) Phase IIb/III
- 10.4 weeks
EFC18418 (CEREN-1)
Chronic Rhinosinusitis with Nasal Polyps Phase III
- 9.8 weeks
- 1st site activated in Canada
EFC18418 (CEREN-1)
Chronic Rhinosinusitis with Nasal Polyps Phase III
- 10.4 weeks
- 2nd site activated in Canada
GenePHIT
Heart Failure Phase II
- 11.6 weeks
- 1st site activated in Canada
GenePHIT
Heart Failure Phase II
- 13 weeks
- Canadian FPI
GenePHIT
Heart Failure Phase II
- 7 weeks
GenePHIT
Heart Failure Phase II
- 9.4 weeks
GenePHIT
Heart Failure Phase II
- 12.6 weeks
GenePHIT
Heart Failure Phase II
- 18.4 weeks
IM045-1018/BALANCE-MSS-1
Neurology Phase II
- 14.8 weeks
INNOVATE
HIV Phase IIb
- 9.8 weeks